Efficacy of Photodynamic Therapy as a Treatment for Gorlin Syndrome-related Basal Cell Carcinomas

Loncaster, Juliette A; Swindell, Ric; Slevin, Finbar; Sheridan, L.; Allan, Donald; Allan, Ernest

doi:10.1016/j.clon.2009.03.004

Cited by 43 publications

(47 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Surgical excision is the traditional gold standard of treatment, with the potential for significant scarring and disfigurement [89]. Adverse effects and variable response rates have limited alternative management options.…”

Section: Gorlin Syndromementioning

confidence: 99%

See 1 more Smart Citation

Photodynamic Therapy and Non-Melanoma Skin Cancer

Griffin

Lear

2016

Cancers

View full text Add to dashboard Cite

Non-melanoma skin cancer (NMSC) is the most common malignancy among the Caucasian population. Photodynamic therapy (PDT) is gaining popularity for the treatment of basal cell carcinoma (BCC), Bowen’s disease (BD) and actinic keratosis (AK). A topical or systemic exogenous photosensitiser, results in selective uptake by malignant cells. Protoporphyrin IX (PpIX) is produced then activated by the introduction of a light source. Daylight-mediated MAL (methyl aminolaevulinate) PDT for AKs has the advantage of decreased pain and better patient tolerance. PDT is an effective treatment for superficial BCC, BD and both individual and field treatment of AKs. Excellent cosmesis can be achieved with high patient satisfaction. Variable results have been reported for nodular BCC, with improved outcomes following pretreatment and repeated PDT cycles. The more aggressive basisquamous, morphoeic infiltrating subtypes of BCC and invasive squamous cell carcinoma (SCC) are not suitable for PDT. Prevention of “field cancerization” in organ transplant recipients on long-term immunosuppression and patients with Gorlin syndrome (naevoid basal cell carcinoma syndrome) is a promising development. The optimisation of PDT techniques with improved photosensitiser delivery to target tissues, new generation photosensitisers and novel light sources may expand the future role of PDT in NMSC management.

show abstract

Section: Gorlin Syndromementioning

confidence: 99%

“…Adverse effects and variable response rates have limited alternative management options. Radiotherapy is contraindicated due to a paradoxical increase in BCCs related to the PTCH mutation [89]. Several small studies have supported the use of MAL-PDT for patients with Gorlin syndrome.…”

Section: Gorlin Syndromementioning

confidence: 99%

Photodynamic Therapy and Non-Melanoma Skin Cancer

Griffin

Lear

2016

Cancers

View full text Add to dashboard Cite

show abstract

“…In one cohort study, 33 patients were treated with either topical PDT for superfi cial lesions (<2 mm thick) or systemic PDT for lesions >2 mm as assessed by ultrasound with overall local control rates of 56 % at 12 months (Loncaster et al 2009 ). In a case report of seven patients, including two children, treated with MAL-PDT, 60 % of lesions were cleared after one session and 78 % after three sessions (Girard et al 2013 ).…”

Section: Nevoid Basal Cell Carcinoma Syndromementioning

confidence: 99%

Photodynamic Therapy for Malignant Skin Lesions

Kaminska

Pei

Tsoukas

2015

European Handbook of Dermatological Treatments

View full text Add to dashboard Cite

“…Se ha visto que la radioterapia puede controlar el CB de forma locorregional durante 4 años hasta en un 86 % de los casos, con un tiempo medio hasta la recurrencia de 40,5 meses 4 . Sin embargo, está contraindicada en el síndrome de Gorlin y en carcinomas basocelulares recurrentes tras radioterapia 5,6 .…”

Section: Comentariosunclassified

Tumoración muy destructiva

Grande-Montalvo

Faura-Berruga

2014

Rev Clin Med Fam

View full text Add to dashboard Cite

RESUMENEl carcinoma basocelular es la neoplasia maligna más frecuente en el ser humano. Se caracteriza por ser localmente invasivo y de crecimiento lento. Presentamos el caso de un paciente con un carcinoma basocelular avanzado, que le causó una marcada destrucción de la región nasal y que por ello no fue susceptible de tratamiento quirúrgico o radioterapia. Para este tipo de pacientes se propone una nueva terapia innovadora, el Vismodegib, una molécula que inhibe la proliferación tumoral y que ha supuesto un gran avance en el manejo de estos pacientes.Palabras clave: Carcinoma basocelular. Destrucción cutánea. Vismodegib. Vía de señalización Hedgehog. ABSTRACT A highly destructive tumourThe basal-cell carcinoma is the most frequent cancer in human beings. It is characterized by being locally invasive and slow-growing. We present the case of a patient with basal cell carcinoma which caused a marked destruction of the nasal region, for which reason he could not be treated surgically or with radiotherapy. For this type of patient, a new innovative therapy is proposed: Vismodegib, a molecule which inhibits the spreading of the tumour and which has signified a great advance in the management of these patients.

show abstract

Efficacy of Photodynamic Therapy as a Treatment for Gorlin Syndrome-related Basal Cell Carcinomas

Cited by 43 publications

References 25 publications

Photodynamic Therapy and Non-Melanoma Skin Cancer

Photodynamic Therapy and Non-Melanoma Skin Cancer

Photodynamic Therapy for Malignant Skin Lesions

Tumoración muy destructiva

Contact Info

Product

Resources

About